🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in the EU / 2025-524359-30-00
Authorised Phase I

Tarlatamab Before and After Surgery for Recurrent High-Grade Glioma

2025-524359-30-00 · tracked via the Priya Life Science EU tracker
Sponsor
Vall D Hebron Institute Of Oncology
Sponsor type
Laboratory/Research/Testing facility
Therapeutic area
Neoplasms
Decision date
22/07/2026
Enrollment target
10
Sites
Spain

Condition studied

surgically resectable recurrent high-grade glioma

Eligibility

Age group
18-64 years, 65+ years
Sex
Female, Male
Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2025-524359-30-00 on CTIS ↗ ← All trials in the EU